TD-HW310016

Codrituzumab(TD-HW310016) is a research-grade recombinant antibody targetingGPC3. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG1-kappa

Monoclonal

GPC3, MXR7, GTR2-2, Glypican-3, Intestinal protein OCI-5, OCI5

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P51654

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

GC33, RG7686, RO5137382, 1365267-33-9

Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer. The specific expression of GPC3 is high in hepatocellular carcinoma (HCC) tissues, which suggests that GPC3 has obvious sensitivity and specificity in the diagnosis of hepatocellular carcinoma, and can be used as a new target for the treatment of hepatocellular carcinoma. Codrituzumab did not show significant inhibition of GPC3 in the phase I trial in combined with sorafenib and the phase II trial placebo-controlled study in patients with advanced liver cancer. Codrituzumab did not show significant inhibition of GPC3 in phase I trials and phase II trials combined with sorafenib in patients with advanced liver cancer. However, the effect of codrituzumab in the treatment of liver cancer is still under study. In 2018, researchers conducted trials such as the distribution of codrituzumab and the impact of overall survival in patients with hepatocellular carcinoma. In the combined analysis of tumor cell surface antigen GPC3 and NK cell surface antigen CD16 in patients with liver cancer, it was found that codrituzumab only had a certain therapeutic effect on patients with high expression level of GPC3 and CD16. These results suggest that GPC3 and CD16 can be used as a composite biomarker to select hepatocellular carcinoma patients for codrituzuma.• Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5., PMID:9133586

SEC-HPLC detection for Research Grade Codrituzumab.　　|　Detects GPC3 in indirect ELISAs.　　|　Flow-cytometry using anti-human GPC3 antibody. HepG2 cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human GPC3 monoclonal antibody (Catalog HW310016, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.　　|　SDS-PAGE for Research Grade Codrituzumab.　　|　Western blot analysis was performed using anti-GPC3 monoclonal antibody at 1μg/ml on various samples.Lane 1:recombinant human GPC3 (Catalog No:TD-HW310011), 50ngLane 2:recombinant human GPC3 (Catalog No:TD-HW310011), 30ng

For research use only. Not suitable for clinical or therapeutic use.